Reliability and Validity of the Arabic Version of the EORTC QLQ-C30 and QLQ-BR23 Questionnaires

Ghufran Jassim1* and Ahmed AlAnsari2

1Department of Family Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, Bahrain
2Training and Education Department, Bahrain Defence Force Hospital, Bahrain

Abstract

Objective: To evaluate the psychometric properties of the Arabic version of the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires.

Materials and methods: A cross-sectional study was carried out on a total of 337 subjects recruited from the Oncology Centre in Bahrain. The European Organization for Research and Treatment-QOL questionnaire and breast cancer specific module (EORTC QLQ-C30 and QLQ-BR23) were used to measure the HRQOL among women with breast cancer. All statistical tests were performed using SPSS Version 20. The reliability of the EORTC QLQ-C30 and QLQ-BR23 questionnaires was examined using Cronbach’s alpha test. The construct validity of both questionnaires was tested using the exploratory factor analysis.

Results: Exploratory factor analysis results of EORTC QLQ-C30 showed that Kaiser-Meyer-Olkin (KMO) Measure of Sampling Adequacy was 0.878 and Bartlett’s Test of Sphericity is < 0.001. The extracted four factor model explained 51.52% of the total variance. Relating to EORTC-QLQ-BR23, the KMO value was 0.735 and Bartlett’s Test of Sphericity showed a significance of (p < 0.001) and extracted a three-factor model which explained a total variance of 46.05%. The Cronbach’s alpha coefficient results for EORTC QLQ-C30 and QLQ BR-23 were 0.927 and 0.844 respectively which reflects high internal consistency.

Conclusion: The EORTC QLQ-C30 and QLQ-BR23 questionnaires are feasible and promising instruments to measure the levels of HRQOL among Arabic speaking women with breast cancer in future studies with some suggested modifications in some of the domains or items.

Keywords
Quality of life, Breast cancer, Validity, EORTC, QLQ

Introduction

Cancer is expected to rank as the leading cause of death and the single most important barrier to increasing life expectancy in every country of the world in the 21st century. Breast cancer remains the most common type of cancer in women [1]. The symptoms of cancer itself, its treatment and complications have a substantial impact on patient’s quality of life. Heath Related Quality of Life (HRQOL) is a multidimensional construct that has proven difficult to define. Generally, HRQOL covers the subjective perceptions of cancer patients’ symptoms, including physical, emotional, social, and cognitive functions and, importantly, disease symptoms and side effects of treatment. It is perceived to be as important as survival in making treatment decision and thus, at present, about 10% of all randomized cancer clinical trials include HRQOL as the main end point [2].

The two well-known and widely used QOL instruments that have been validated across cultures for breast cancer are the European Organization for Research and Treatment (EORTC) QLQ-C30 and QLQ-BR23 measures [3].

The QLQ-C30 questionnaire was developed in 1980 by European Organization for Research and Treatment of Cancer (EORTC) and consists of 30 items. EORTC-BR23 was developed by Spranger, et al. specifically for breast cancer patients which must be used in combination with EORTC-C30 and consists of 23 items [4].

Citation: Jassim G, AlAnsari A (2020) Reliability and Validity of the Arabic Version of the EORTC QLQ-C30 and QLQ-BR23 Questionnaires. Int Arch Intern Med 4:030. doi.org/10.23937/2643-4466/1710030

Accepted: October 17, 2020; Published: October 19, 2020
Copyright: © 2020 Jassim G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Many studies evaluated the quality of life of breast cancer survivors. In Bahrain, quality of life of breast cancer survivors has been reported in a cross-sectional study on 337 Bahraini women with breast cancer and in a qualitative study on 12 patients [5,6].

Breast cancer is ranked as the most prevalent cancer among women in Bahrain. Statistics revealed that the women aged less than 40 years make up a larger percentage of total breast cancer cases than do their counterparts in Western countries [7,8]. A review of the epidemiological pattern of breast cancer in Bahrain between 2000 and 2010 revealed that the median age at diagnosis during the 11-year period was 49 years with the highest percentage of cases occurring in the age group 45-49 [9]. In addition, Bahraini women similar to other Arab women face cultural taboos surrounding breast cancer [8,10].

Ranking as the most prevalent cancer among women in the Arab world, the younger age at diagnosis and the unique cultural norms and values all suggest that information on Quality of Life (QoL) in this region may be specific and hence important to both health care providers and patients. Therefore, it would be necessary to evaluate the appropriateness of using the EORTC-C30 and BR23 questionnaires in Bahrain as the cultural and social context may be different from the socio-cultural setting of other countries.

Few studies have evaluated the psychometric properties of the Arabic version of the two questionnaires [11-15]. However, they were either conducted on a non-probability sample of cancer survivors or included a small sample size or used local spoken language rather than the official Arabic language [15,16]. Further, none of these studies conducted exploratory factor analysis to assess construct validity, although it is considered one of the strongest approaches to establishing construct validity, and is the most commonly used method for establishing construct validity measured by an instrument [17]. The only exception is the Lebanese study which used confirmatory rather than exploratory factor analysis [14].

The objective of this study is to evaluate the psychometric properties of the Arabic version of the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires on a representative sample of women with breast cancer at different stages of diagnosis and different times of survival.

Our specific objectives are to assess: i) Internal consistency of the EORTC QLQ-C30 and BR23; ii) Item-total correlation and; iii) Exploratory factor analysis.

Methods

This was a cross-sectional study on a random sample of 337 Bahraini women with breast cancer. The sample was drawn from Bahrain Cancer Registry across a 9-year period. Quality of life was assessed using the Arabic version of the European Organization for Research and Treatment of Cancer QoL Cancer Specific Version (EORTC QLQ-C30, v.3.0) and breast cancer specific EORTC QLQ-BR23. Sampling and recruitment are described explicitly in the original study [5]. Ethical approval was sought from an RCSI Bahrain and Ministry of health ethics committees.

The QLQ-C30 consists of 30 items measuring “Global Health status (2 items), Functional scales (15 items) and Symptoms scales/items (13 items). Items were measured using a 4-point Likert Scale ranging from Not at all (1) to Very much (4) (Table 1).

EORTC-BR23 consists of 23 items which measure two main scales “Functional Scale (8 items) and “Symptoms scales (15 items). Items measured using 4-point Likert Scale ranging from Not at all (1) to Very much (4) (Table 2).

We followed the supplemental scoring manual in the analysis. As instructed in the manual, scores were transformed to range from 0 to 100 in order to standardise the raw score. A higher score represents a higher (better) level of functioning or a higher (worse) level of symptoms.

The reliability (Internal consistency) of the whole instrument and the separate scales was measured using Cronbach’s alpha whereas construct validity was measured using the exploratory factor analysis which was done using principal component analysis method with varimax rotation.

The data was first checked for suitability and ade-
Results

In total data was collected from 239 participants with an average age (SD) of 50.2 (11.1) and a median of 48 years. Mean time elapsed since diagnosis was 4.22 (SD ± 2.69) years.

EORTC QLQ-30 (version 3.0)

Item 29 and 30 assessing the Global Health Status were excluded from the analysis as the scales were ranging from 1 to 6 (Very poor to Excellent) while the remaining 28 items were measured on a 4-point Likert Scale (Not at all to Very much).

Factor analysis: Exploratory factor analysis (with Varimax rotation) showed that Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy was 0.878 (above the commonly recommended value of 0.6), and Bartlett’s Test of Sphericity was significant < 0.00. This indicates that a factor analysis may be useful with our data and that the variables are related and therefore suitable for structure detection. The four factors explained 51.52%

Table 2: Scoring the QLQ-BR 23.

| Functional scales | Number of items | Item range | Version 3.0 Item numbers |
|-------------------|----------------|------------|--------------------------|
| Body image        | 4              | 3          | 39-42                    |
| Sexual functioning| 2              | 3          | 44, 45                   |
| Sexual enjoyment  | 1              | 3          | 46                       |
| Future perspective| 1              | 3          | 43                       |

| Symptoms scales/Items | Number of items | Item range | Version 3.0 Item numbers |
|-----------------------|----------------|------------|--------------------------|
| Systemic side effect  | 7              | 3          | 31-34, 36, 37, 38        |
| Breast symptoms       | 4              | 3          | 50-53                    |
| Arm symptoms          | 3              | 3          | 47, 48, 49               |
| Upset by hair loss    | 1              | 3          | 35                       |

Table 3: Exploratory factor analysis.

| Items | Factor 1 (Physical and role) | Factor 2 (Emotion) | Factor 3 (Pain and cognition) | Factor 4 (Systemic symptoms) |
|-------|------------------------------|--------------------|------------------------------|-----------------------------|
| Q1    | 0.622                        |                    |                              |                             |
| Q2    | 0.712                        |                    |                              |                             |
| Q3    | 0.593                        |                    |                              |                             |
| Q4    | 0.520                        |                    |                              |                             |
| Q5    |                              | 0.438              |                              |                             |
| Q6    | 0.686                        |                    |                              |                             |
| Q7    | 0.687                        |                    |                              |                             |
| Q8    | 0.556                        |                    |                              |                             |
| Q9    |                              | 0.545              |                              |                             |
| Q10   | 0.700                        |                    |                              |                             |
| Q11   | 0.440                        |                    |                              |                             |
| Q12   | 0.596                        |                    |                              |                             |
| Q13   |                              | 0.555              |                              |                             |
| Q14   |                              | 0.757              |                              |                             |
| Q15   |                              | 0.800              |                              |                             |
| Q16   |                              | 0.494              |                              |                             |
| Q17   |                              |                    |                              |                             |
| Q18   |                              | 0.500              |                              |                             |
| Q19   |                              | 0.730              |                              |                             |
| Q20   |                              |                    |                              |                             |
| Q21   |                              | 0.844              |                              |                             |
| Q22   |                              | 0.859              |                              |                             |
| Q23   |                              | 0.678              |                              |                             |
| Q24   |                              | 0.631              |                              |                             |
| Q25   |                              | 0.618              |                              |                             |
| Q26   | 0.464                        |                    |                              |                             |
| Q27   | 0.485                        |                    |                              |                             |
of the total variance. Item 28 (Has your physical condition or medical treatment caused you financial difficulties?) did not load any of the four factors and was removed from further analyses. Table 3 explains the factors loading.

The first factor loaded significantly, with the exception of Q5, all items of physical scale (Q1, Q2, Q3, Q4) and role (Q6, Q7) scales with factor loading ranging from 0.31 to 0.71; the second factor loaded significantly all items of emotional scale (Q21, Q22, Q23, Q24) with factor loading ranging from 0.31 to 0.85. The third factor loaded significantly all items of pain and fatigue (Q9, Q19, Q18) and cognitive scale (Q20, Q25) with factor loading ranging from 0.30 to 0.75. The fourth factor loaded significantly all items of appetite loss (Q13), nausea and vomiting (Q14), constipation (Q16) and diarrhoea (Q17) scales with factor loading ranging from 0.31 to 0.80.

Internal consistency reliability: We checked the overall reliability of the instrument and the four factors

| Factors | Items | Mean | SD  | Corrected item total correlation | Cronbach’s alpha |
|---------|-------|------|-----|----------------------------------|------------------|
| Factor 1 (Physical and role) | Q1 | 2.41 | 1.210 | 0.539 | 0.881 |
| | Q2 | 2.33 | 1.212 | 0.643 | |
| | Q3 | 1.41 | 0.862 | 0.548 | |
| | Q4 | 1.54 | 0.890 | 0.456 | |
| | Q6 | 1.97 | 1.119 | 0.694 | |
| | Q7 | 1.90 | 1.129 | 0.703 | |
| | Q8 | 1.61 | 0.912 | 0.627 | |
| | Q10 | 2.13 | 1.039 | 0.724 | |
| | Q11 | 1.91 | 1.181 | 0.508 | |
| | Q12 | 2.18 | 1.122 | 0.682 | |
| Factor 2 (Emotions) | Q21 | 2.20 | 1.190 | 0.793 | 0.842 |
| | Q22 | 2.19 | 1.176 | 0.796 | |
| | Q23 | 2.13 | 1.136 | 0.612 | |
| | Q24 | 1.81 | 1.163 | 0.651 | |
| | Q26 | 1.71 | 1.107 | 0.403 | |
| | Q27 | 1.64 | 1.094 | 0.479 | |
| Factor 3 (Pain and cognition) | Q9 | 2.01 | 1.061 | 0.575 | 0.808 |
| | Q18 | 1.88 | 1.101 | 0.591 | |
| | Q19 | 1.77 | 1.091 | 0.663 | |
| | Q20 | 1.66 | 1.013 | 0.681 | |
| | Q25 | 1.93 | 1.039 | 0.467 | |
| Factor 4 (Systemic side effect) | Q5 | 1.04 | 0.281 | 0.587 | 0.700 |
| | Q13 | 1.40 | 0.830 | 0.624 | |
| | Q14 | 1.36 | 0.759 | 0.352 | |
| | Q15 | 1.18 | 0.604 | 0.319 | |
| | Q16 | 1.54 | 0.921 | 0.225 | |
| | Q17 | 1.21 | 0.570 | 0.510 | |

Table 5: Inter-scale correlations of EORTC QLQ-C30.

|          | Factor 1 (Physical) | Factor 2 (Emotion) | Factor 3 (Cognition) | Factor 4 (Systemic side effect) |
|----------|---------------------|--------------------|----------------------|---------------------------------|
| Factor 1 (Physical) | 1                   |                     |                      |                                 |
| Factor 2 (Emotion)  | 0.512**             | 1                   |                      |                                 |
| Factor 3 (Cognition) | 0.604**             | 0.549**            | 1                    |                                 |
| Factor 4 (Systemic side effect) | 0.438** | 0.394** | 0.426**               | 1                               |

**Correlation is significant at the 0.01 level (2-tailed).
rotation and extracted a three-factor model, which explained a total variance of 46.05%.

The inter-scale correlation of EORTC QLQ-C30 was tested and presented in Table 5. Factors 1 and factor 3 showed the highest correlation coefficient (0.60). The inter-scale correlations for the EORTC QLQ-C30 ranged from 0.39 (p < 0.01) between factor 2 and factor 4 to 0.60 (P < 0.01) between factor 1 and factor 3.

**EORTC-QLQ-BR23**

**Factor analysis:** The instrument was suitable for the analysis and the sample was adequate for an exploratory factor analysis. The sample was adequate for an exploratory factor analysis demonstrated by the KMO value of 0.735 and Bartlett’s Test of Sphericity significance of (p < 0.001). The exploratory factor analysis was done using principal component analysis method with varimax rotation and extracted a three-factor model, which explained a total variance of 46.05%.

Factor loading is presented in Table 6 and shows that factor 1 loaded significantly all items of body image scale (Q39, Q40, Q41, Q42) with factor loading ranging from 0.39 to 0.80. Factor 2 loaded significantly all items of arm symptoms (Q47, Q48, Q49) and breast symptoms scales (Q50, Q51, Q52, Q53) with factor loading ranging from 0.44 to 0.77. Factor three loaded significantly almost all items of systemic side effects scale (Q31, Q32, Q34, Q36, Q37) with factor loading ranging from 0.38 to 0.73.

**Internal consistency reliability:** The overall reliability of the instrument was 0.844, which is higher than the minimum required 0.70. The reliability of each item is explained in Table 4 and shows that factor 1 has the highest reliability (Cronbach’s alpha 0.79).

Item 35 (Were you upset by the loss of your hair?)

---

**Table 6: EORTC-QLQ-BR23: Exploratory factor analysis factor loadings and reliability analysis: Internal consistency reliability and item-total correlation.**

| Items | Mean | SD   | Factors | Corrected item-total correlation | Cronbach’s alpha |
|-------|------|------|---------|----------------------------------|-----------------|
|       |      |      | Factor 1 (Body image) | Factor 2 (Arm and breast symptoms) | Factor 3 (Systemic side effect) |
| Q31   | 1.85 | 1.074| 0.529 | 0.404 | 0.635 |
| Q32   | 1.32 | 0.776| 0.737 | 0.479 |
| Q33   | 1.4  | 0.757| 0.389 | 0.294 |
| Q34   | 1.71 | 1.038| 0.524 | 0.310 |
| Q36   | 1.62 | 0.937| 0.529 | 0.367 |
| Q37   | 1.2  | 0.637| 0.534 | 0.407 |
| Q39   | 1.71 | 1.085| 0.782 | 0.661 | 0.795 |
| Q40   | 1.79 | 1.121| 0.799 | 0.662 |
| Q41   | 1.78 | 1.136| 0.803 | 0.653 |
| Q42   | 1.65 | 1.043| 0.780 | 0.604 |
| Q43   | 2.16 | 1.185| 0.396 | 0.335 |
| Q47   | 2.48 | 1.181| 0.544 | 0.618 |
| Q48   | 1.79 | 1.097| 0.497 | 0.486 | 0.775 |
| Q49   | 2.03 | 1.147| 0.616 | 0.660 |
| Q50   | 1.74 | 0.937| 0.633 | 0.519 |
| Q51   | 1.22 | 0.587| 0.441 | 0.334 |
| Q52   | 1.3  | 0.701| 0.777 | 0.467 |
| Q53   | 1.39 | 0.789| 0.677 | 0.424 |

---

**Table 7: Inter-scale correlations of EORTC QLQ-BR23.**

| Factors | Factor 1 (Body image) | Factor 2 (Arm and breast symptoms) | Factor 3 (Systemic side effect) |
|---------|-----------------------|-----------------------------------|---------------------------------|
| Factor 1 (Body image) | 1 | 0.466** | 0.389** |
| Factor 2 (Arm and breast symptoms) | 1 | 0.316** | 1 |
| Factor 3 (Systemic side effect) | 1 | 1 | 1 |

**Correlation is significant at the 0.01 level (2-tailed).**
did not load on any of the factors. During the reliability analysis items 38 (Did you have headaches?), 44 (To what extent were you interested in sex?), 45 (To what extent were you sexually active?) and 46 (To what extent was sex enjoyable for you?) were removed because of the low reliability.

Table 7 presents the inter-scale correlation of BR23 and shows that factors 1 and 2 have the highest correlation coefficient (0.466).

Discussion

This study assessed the reliability and construct validity of the EORTC QLQ-C30 and BR32 in a sample of 337 Bahraini women with breast cancer. Internal consistency reliability revealed high correlation coefficients for the total scale of both QLQ-C30 and BR32 (0.927 and 0.844 respectively) indicating good overall internal consistency. Our results were similar and confirmative in the area of reliability with other reported studies in Kuwait [11], United Arab of Emirates [12], Qatar [13], Morocco [15,16] and in Lebanon [14].

In this study, the coefficient was estimated for each multi-item scale of the EORTC QLQ-C30 and showed coefficients ranging between 0.22 to 0.79. The lowest (< 0.4) was reported for questions: 15, 16, and 17. For BR32, the coefficients of each item ranged between 0.29 and 0.66 with the lowest (< 0.4) reported for questions 33, 34, 36, 43 and 51.

Items 44 (To what extent were you interested in sex?), 45 (To what extent were you sexually active?) and 46 (To what extent was sex enjoyable for you?) were removed from reliability analysis because of very low coefficient values. This is not a surprising finding as sexuality is considered a very private topic and women are more conservative about their sex related issues. The same was reported in similar conservative cultures [19].

Few reports assessed the validity of the Arabic version of the EORTC QLQ-C30 with or without the breast cancer specific BR23 utilizing various methods and psychometric indices; for example, multi trait scaling analysis, convergent and discriminant validity of items, and known group comparison [11-16]. However, none of these reports used factor analysis with the exception of the Lebanese study, which used confirmatory and not exploratory factor analysis [14]. Therefore, in the present study, we focused on exploratory factor analysis to test the construct validity of the Arabic version of the QLQ-C30 and BR23 tool.

We conducted factor analysis to to identify the nature of the factors underlying the set of measures in the questionnaire. Principle component analysis extracted four factors for the C30 tool. These Factors explained 51.52% of the total variance. Further, the analysis showed that all the items of physical and role functioning scale were loaded on one factor. This is consistent with studies conducted elsewhere [20-22] and indicates that both the scales may not be separable. The fifth item of the physical functioning scale did not load factor one instead it clustered itself with the fourth factor. Similar problems with this item have been reported in the literature [22,23]. In congruent with other studies [20], the second factor addressed the emotional issues of cancer patients and this was evident in the fact that this factor loaded all items of emotional scale. The third factor loaded pain, fatigue and cognitive scales. One of the possible explanations is that concentration problems might in fact be due to pain or fatigue rather than memory problems. Further, cognitive scale have consistently shown suboptimal Cronbach’s alphas in the literature for various languages including Arabic [11-14,22,24].

The fourth factor loaded appetite loss, nausea, vomiting, constipation and diarrhea in one factor. All are gastrointestinal symptoms and hence may be not separable as they are closely related in terms of their clinical presentation. The same was reported in other studies [20], which indicate that these scales are probably indistinguishable and best to be combined in one symptom scale. Item 28 (financial difficulties) did not load any of the factors which could be explained by the fact that health care including cancer treatment is free of charge for nationals in Bahrain and inmost Arabian Gulf countries [25].

For the BR23 tool, three factors were identified and they explained a total variance of 46.05%. All items of body image were loaded on the first factor whereas items related to systemic side effects loaded the third factor. Items of Arm and breast symptoms were loaded on the second factor, which indicates that they are closely related and may not be separable and would best be considered as one scale. Item 35 (hair loss) did not load in any of the factors and one possible explanation is that the study included women at different phases of their treatment journey whereas hair loss is usually experienced during the early stages of treatment. Other studies also reported the same issue with this item [19].

One of the limitations is the rarity of this type of construct validity assessment in the studies examining the validity of the Arabic version of the QLQ-C30 and BR23 questionnaire. Therefore, the comparability of our result with other studies in the region becomes a challenging task. Another limitation is that some of the studies testing the validity of the Arabic version have used local spoken languages [15] rather than the standard official Arabic language that was used in our study which might threaten the precision of our comparison.

Conclusion

This study revealed that the Arabic version of EORTC QLQ-C30 and its breast cancer specific BR23 instrument is reliable and valid with some suggested modifications in some of the domains or items.
References

1. Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424.

2. Bottomley A (2002) The cancer patient and quality of life. Oncologist 7: 120-125.

3. Hui-Yan Niu, Chun-Ying Niu, Jia-He Wang, Yi Zhang, Ping He (2014) Health-related quality of life in women with breast cancer: A literature-based review of psychometric properties of breast cancer-specific measures. Asian Pac J Cancer Prev 15: 3533-3536.

4. Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, et al. (1998) The European Organization for research and treatment of cancer approach to developing questionnaire modules: An update and overview. EORTC quality of life study group. Qual Life Res 7: 291-300.

5. Jassim GA, Whitford DL (2013) Quality of life of Bahraini women with breast cancer: A cross sectional study. BMC Cancer 13: 212.

6. Jassim GA, Whitford DL (2014) Understanding the experiences and quality of life issues of Bahraini women with breast cancer. Soc Sci Med 107: 189-195.

7. Fakhro AE, Fateha BE, Al-Asheeri N, Al-Ekri SA (1999) Breast cancer: Patient characteristics and survival analysis at Salmaniya medical complex, Bahrain. East Mediterr Health J 5: 430-439.

8. Nagi SES, Mazen KK, Toufic E, Abdul Rahman EK, Maya C, et al. (2007) Trends in epidemiology and management of breast cancer in developing Arab countries: A literature and registry analysis. Int J Surg 5: 225-233.

9. Randah RH, Najat MA, Majeda AF, Hala E Al-Mehza (2014) Epidemiology of breast cancer among Bahraini women: Data from the Bahrain cancer registry. Sultan Qaboos Univ Med J 14: 176-182.

10. Abu-Naser D (2007) Arab women who have breast cancer face taboo.

11. Alawadhi SA, Ohaeri JU (2010) Validity and reliability of the European Organization for research and treatment in cancer quality of life questionnaire (EORTC QLQ): Experience from Kuwait using a sample of women with breast cancer. Ann Saudi Med 30: 390-396.

12. Awad MA, Denic S, El Taji H (2008) Validation of the European Organization for research and treatment of cancer quality of life questionnaires for Arabic-speaking populations. Ann N Y Acad Sci 1138: 146-154.

13. Abdulbari Bener, Reem Alsalimah, Lisa Doodson, Hanadi R El Ayoubi (2017) An assessment of reliability and validity of the European Organization for research and treatment of cancer quality of life questionnaire C30 among breast cancer patients in Qatar. J Family Med Prim Care 6: 824-831.

14. Huijer HA, Sagherian K, Tamim H (2013) Validation of the Arabic version of the EORTC quality of life questionnaire among cancer patients in Lebanon. Qual Life Res 22: 1473-1481.

15. Chakib Nejjari, Samira El Fakir, Karima Bendahhou, Karima El Rhazi, Naima Abda, et al. (2014) Translation and validation of European Organization for research and treatment of cancer quality of life questionnaire-C30 into Moroccan version for cancer patients in Morocco. BMC Res Notes 7: 228.

16. Samira El Fakir, Naima Abda, Karima Bendahhou, Ahmed Zidouh, Maria Bennani, et al. (2014) The European Organization for research and treatment of cancer quality of life questionnaire-BR23 breast cancer-specific quality of life questionnaire: Psychometric properties in a Moroccan sample of breast cancer patients. BMC Res Notes 7: 53.

17. Kang H (2013) A guide on the use of factor analysis in the assessment of construct validity. J Korean Acad Nurs 43: 587-594.

18. Stevens J (1986) Applied multivariate statistics for the social sciences. Hillsdale NJ: Lawrence Erlbaum Associates.

19. Qing Chen, Shunping Li, Min Wang, Liu Liu, Gang Chen (2018) Health-related quality of life among women breast cancer patients in eastern China. J BioMed Res Int 12.

20. Barman MP, Hazarika J, Kalita A (2012) Reliability and validity of Assamese version of EORTC QLQ-C30 questionnaire for studying the quality of life of cancer patients of Assam. WASJ 17: 672-678.

21. Guzelant A, Goksel T, Ozkok S, Tasbakan S, Aysan T, et al. (2004) The European Organization for research and treatment of cancer QLQ-C30: An examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30. Eur J Cancer Care 20: 354-361.

22. Eun-Hyun Lee, Mison Chun, Hee-Jung Wang, Ho Yeong Lim, Jin-Hyuk Choi (2005) Multidimensional constructs of the EORTC quality of life questionnaire (QLQ-C30) in Korean cancer patients with heterogeneous diagnoses. Cancer Res Treat 37: 148-156.

23. Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, et al. (1995) The EORTC core quality of life questionnaire (QLQ-C30): Validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 31: 2260-2263.

24. Kontodimopoulos N, Nitoulias K, Niakas D (2011) Validity of the Greek EORTC QLQ-C30 and QLQ-BR23 for measuring health-related quality of life in breast cancer patients. Eur J Cancer Care 20: 354-361.

25. Health system profile-Bahrain, World Health Organisation.